Bilateral Acute Angle Closure in a Pediatric Patient Taking Lisdexamfetamine Dimesylate (Vyvanse).
Davanian Arash M, Fitzpatrick John C, Tran Duy P, Korducki John P, Groth Sylvia L
AI Summary
A 14-year-old on Vyvanse developed bilateral acute angle closure, which resolved upon discontinuing the medication. This highlights a rare but critical drug-induced glaucoma risk in pediatric patients.
Abstract
Attention-deficit/hyperactivity disorder is commonly treated with amphetamines as first line therapy. Rare case reports have shown amphetamines are associated with open angle glaucoma. We report a rare case of a 14-year-old male who presented with bilateral acute angle closure presumed to be related to his use of lisdexamfetamine dimesylate (Vyvanse). The patient's medication was discontinued which resulted in complete resolution of angle closure.
MeSH Terms
Shields Classification
Key Concepts4
A 14-year-old male presented with bilateral acute angle closure presumed to be related to his use of lisdexamfetamine dimesylate (Vyvanse).
Discontinuation of lisdexamfetamine dimesylate (Vyvanse) resulted in complete resolution of angle closure in a 14-year-old male with bilateral acute angle closure.
Amphetamines are commonly used as first-line therapy for attention-deficit/hyperactivity disorder.
Rare case reports have shown amphetamines are associated with open angle glaucoma.
Related Articles5
Thymoxamine hydrochloride: an alpha-adrenergic blocker.
Basic ScienceAcute angle-closure glaucoma following botulinum toxin injection for blepharospasm.
Case ReportAcute angle-closure glaucoma following botulinum toxin.
Case ReportAcute angle closure glaucoma associated with nebulised ipratropium bromide and salbutamol.
Case ReportAcute closed-angle glaucoma after arteriovenous fistulas.
Case SeriesIs this article assigned to the wrong chapter(s)? Let us know.